MiniMed Group (MMED) analyst forecast and price target
Analyst forecast
Consensus of 13 analyst ratings
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| UBS | Initiated Coverage | Buy | $25.00 | Jul 28, 2026 |
| Wells Fargo | Maintained | Overweight | $22.00 from $26.00 | Jun 4, 2026 |
| B of A Securities | Maintained | Buy | $20.00 from $27.00 | May 18, 2026 |
| Benchmark | Initiated Coverage | Buy | $20.00 | May 12, 2026 |
| Barclays | Initiated Coverage | Overweight | $26.00 | Apr 1, 2026 |
| Mizuho | Initiated Coverage | Outperform | $21.00 | Mar 31, 2026 |
| Piper Sandler | Initiated Coverage | Neutral | $16.00 | Mar 31, 2026 |
| Evercore ISI Group | Initiated Coverage | Outperform | $20.00 | Mar 31, 2026 |
| Morgan Stanley | Initiated Coverage | Overweight | $19.00 | Mar 31, 2026 |
| B of A Securities | Initiated Coverage | Buy | $27.00 | Mar 31, 2026 |
| BTIG | Initiated Coverage | Buy | $25.00 | Mar 31, 2026 |
| Wells Fargo | Initiated Coverage | Overweight | $26.00 | Mar 31, 2026 |
| Citigroup | Initiated Coverage | Buy | $23.00 | Mar 31, 2026 |
| William Blair | Initiated Coverage | Outperform | — | Mar 31, 2026 |
Frequently asked questions
Is MMED a buy, sell, or hold?
Analysts covering MiniMed Group currently average a Buy rating: 11 buy, 1 hold and 1 sell, from 13 analysts. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on MMED?
On Jul 28, 2026, UBS initiated coverage of MiniMed Group at Buy with a price target of $25.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.